Researchers investigate gene network to identify “cancer driver genes”
The new study looked at the network of gene-gene interactions associated with cancer onset and progression to identify therapeutic targets.
List view / Grid view
The new study looked at the network of gene-gene interactions associated with cancer onset and progression to identify therapeutic targets.
A new study provides an in-depth review on the designs and applications of morphology-transformable nanoparticles to improve cancer therapies.
Scientists identified three prototypical RNA-expression states and revealed differences in their susceptibility to a variety of cancer drugs.
Scientists used a new screen to identify FAM72A as a cause of mutagenesis that affects antibody development in COVID-19 and cancer.
The new study used cryo-electron microscopy to visualise the structure of a HAT protein and uncover compounds for drug development.
In this article, Drug Target Review's Victoria Rees explores a new method that could enable powerful immune cells to be produced in large quantities to treat a range of cancers.
The new findings suggest that inhibiting p53 can reduce CRISPR-associated cancer risks and may lead to developments in precision medicine.
The UTX gene mutation was found to lead to an increased cancer risk, presenting a potential drug target for preventative therapies.
Scientists have used nuclear magnetic resonance (NMR) spectroscopy to investigate the protein p53, which they say could advance cancer studies.
A new label-free technique has been developed for molecularly specific exosome biosensing in diagnostics and biomarker detection.
Watch this exclusive interview with Professor Ann Ager, Cardiff University, to discover how CAR T cells could be targeted against solid tumours.
Washington University will receive $7.5 million from the NIH to study senescent cells for treatments against age-related diseases.
In a new study, a calorie-restricted diet significantly reduced tumour growth in mouse models, suggesting new possibilities for cancer therapies.
Medicenna's IL-2 super-agonist, MDNA11, successfully induced antitumour cells in animal models, a pre-clinical study has revealed.
In this article, Professor Forest White, Department of Biological Engineering at MIT, and Dr Lauren Stopfer, Scientist at BioNTech, present a novel assay approach for the rapid, reproducible and accurate identification of potential therapeutic targets using mass spectrometry.